John Tower, DO
Rheumatology · Rochester Hills, MINPI 1558329359
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Amgen accounts for 62.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $7,939 and has fallen 56.2% since, to $3,476 in 2025.
Across 676 payments — averaging $51.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- Johnson & Johnson$3K
- AbbVie$3K
- UCB, Inc.$2K
- AstraZeneca$1K
- Novartis$874
- plus $3K from 20 others
What the payments were for
- Consulting fees$1,2954%
- Speaking & faculty fees$18,55053%
- Grants$2401%
- Travel & lodging$7242%
- Food & beverage$13,46539%
- Education$5312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 234 | $21,770 |
| Johnson & Johnson | 109 | $3,026 |
| AbbVie | 114 | $2,573 |
| UCB, Inc. | 14 | $1,877 |
| AstraZeneca(2 entities) | 6 | $1,458 |
| Novartis | 43 | $874 |
| Pfizer | 40 | $608 |
| E.r. Squibb & Sons, L.L.C. | 46 | $537 |
| GSK | 16 | $485 |
| Lilly USA, LLC | 17 | $320 |
| Sanofi | 6 | $238 |
| Janssen Scientific Affairs, LLC | 2 | $236 |
| Genentech USA, Inc. | 7 | $125 |
| Intrafusion GP, LLC | 1 | $110 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Pacira Therapeutics, Inc. | 3 | $77 |
| Sandoz | 3 | $72 |
| Aurinia Pharma U.S., Inc. | 3 | $71 |
| Fresenius Kabi USA, LLC | 2 | $56 |
| Boehringer Ingelheim | 2 | $53 |
| Organon | 2 | $41 |
| Sobi, Inc | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Merck | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Bioventus LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,805 in reported general payments places this provider in the 85th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 62 | $496,294 |
| Humira PenAdalimumab | 42 | $287,037 |
| Humira(Cf) PenAdalimumab | 29 | $274,981 |
| EnbrelEtanercept | 22 | $146,407 |
| XeljanzTofacitinib Citrate | 26 | $143,388 |
| Xeljanz XrTofacitinib Citrate | 25 | $136,349 |
| HumiraAdalimumab | 12 | $81,740 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $74,520 |
| OtezlaApremilast | 16 | $72,523 |
| Hydroxychloroquine Sulfate | 357 | $26,277 |
| OtrexupMethotrexate/Pf | 17 | $16,314 |
| MethotrexateMethotrexate Sodium | 303 | $11,871 |
| Celecoxib | 186 | $7,939 |
| Gabapentin | 501 | $7,713 |
| Sulfasalazine | 186 | $6,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $21,770 | $218,93038 claims |
| PfizerXeljanz | $608 | $143,38826 claims |
| AbbVieHumira | $2,573 | $81,74012 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,877 | $74,52011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Rochester Hills
- Roman CzubatyjRochester Hills$764K
- Patricia CagnoliRochester Hills$89K
- Dana RockwellRochester Hills$16K
- Josephine AlootRochester Hills$15K
- Phyllis BirkelRochester Hills$14K
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
- Delfin SantosRochester$242K
- Allan MortonWarren$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.